Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics...
Molecular Imaging
Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.
News | Prostate Cancer | December 14, 2016
December 14, 2016 — Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on...
News | Nuclear Imaging | December 12, 2016
Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be...
Sponsored Content
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and...
News | Radiation Dose Management | December 08, 2016
December 8, 2016 — Numa introduced a new software application at the 2016 Annual Meeting of the Radiological Society...
In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.
News | Nuclear Imaging | December 06, 2016
December 6, 2016 — Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac...
News | SPECT Imaging | December 06, 2016
December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America...
Sponsored Content
Staging F18FDG PET/CT images of adenocarcinoma in the RUL (right upper lobe) of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. (Images courtesy of Dr. Jay Kikut and UVMC)
Blog | PET-CT | October 25, 2018
Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both.
Uptake of 89Zr-11B6 in the prostate of a transgenic mouse with prostate cancer. Image courtesy of Daniel Thorek
News | Prostate Cancer | November 30, 2016
November 30, 2016 — An international group of researchers report success in mice of a method of using...
Technology | Breast Imaging | November 28, 2016
November 28, 2016 — Dilon Diagnostics and GE Healthcare announced the U.S. Food and Drug Administration (FDA)...
News | Women's Health | November 16, 2016
November 16, 2016 — Dilon Diagnostics and GE Healthcare announced the signing of an agreement for Dilon to be the...
News | Radiation Dose Management | November 10, 2016
November 10, 2016 — Medic Vision Imaging Solutions Ltd. announced recently that the company has tripled its growth....
Graphic courtesy of Pixabay
Blog | Radiology Imaging | November 09, 2016
Much has been said about the potential of outcomes to change the practice of medicine. Through comparative studies,...
News | Breast Imaging | November 07, 2016
November 7, 2016 — Gamma Medica announced that Henry Ford Health System (Detroit) has purchased Gamma Medica’s...
Researchers at Washington University School of Medicine in St. Louis have developed a chemical compound that detects the Alzheimer’s protein amyloid beta better than current FDA-approved agents. The compound potentially may be used in brain scans to identify people in the earliest stages of Alzheimer’s disease. In the image, the compound has passed from the bloodstream of a living mouse into its brain, where it is detected by a positron emission tomography (PET) scan. Arrows indicate clumps of amyloid beta. Credit Ping Yan and Jin-Moo Lee.
News | Radiopharmaceuticals and Tracers | November 02, 2016
November 2, 2016 — By the time unambiguous signs of memory loss and cognitive decline appear in people with...
Application of dual-modality optical and PET/CT activity-based probe in experimental carotid inflammation model. Coronal noninvasive PET/CT scans of (A) healthy and (B) diseased mice with and without ligated carotid arteries respectively. Inset images show optical ex vivo florescence imagining of (A) healthy and (B) diseased carotid arteries. PET/CT and optical images courtesy of Xiaowei Ma, Toshinobu Saito and Nimali Withana.
News | PET-CT | November 01, 2016
November 1, 2016 — Researchers at Stanford University have demonstrated for the first time the use of a dual optical...
News | Radiopharmaceuticals and Tracers | October 28, 2016
October 28, 2016 — The National Academies of Sciences, Engineering, and Medicine (NAS) have released a report on the...
News | Prostate Cancer | October 25, 2016
October 25, 2016 — Blue Earth Diagnostics Ltd. announced the peer-reviewed publication of results from a Phase 3...
Technology | SPECT-CT | October 18, 2016
October 18, 2016 — At the 2016 annual meeting of the Radiological Society of North America (RSNA 2016), Siemens...
News | Radiopharmaceuticals and Tracers | October 17, 2016
October 17, 2016 — Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3...
IQon Spectral CT image courtesy of Philips Healthcare
News | Information Technology | October 13, 2016
October 13, 2016 — Philips announced that it will be displaying a variety of solutions aimed at increasing...
Panel A shows a flank A549 lung tumor in a nude mouse with combined 18F-FDG PET uptake (signal intensity in color) and T2-weighted anatomical MRI (grayscale). Panel B shows a similar tumor image with a relative permeability map for the tumor (color code) overlaid on a corresponding anatomical MRI reference. Regions identified as necrotic were not included in the DCE MRI analysis. Image courtesy of the University of Arizona Department of Medical Imaging.
News | PET-MRI | October 13, 2016
October 13, 2016 — Cubresa Inc. recently announced the successful installation of their compact positron emission...
